SCHEMBL3494947

SCHEMBL3494947

CCC(C)NC(=O)C1C2CCC(O2)C1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.53
KDM4E B2RXH2 3/20 0.53
TFPI2 P48307 2/20 0.53
GMNN O75496 1/20 0.53
PMP22 Q01453 1/20 0.53
TP53 P04637 1/20 0.53
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.53
THPO P40225 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.51
PPM1B O75688 4/20 0.50
PTPN1 P18031 3/20 0.50
PPP1CC P36873 3/20 0.50
PPP1CA P62136 1/20 0.49
ALDH1A1 P00352 4/20 0.45
HTT P42858 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
FPR1 P21462 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3495128 0.77 LMNA (0.61) LMNAKDM4ETFPI2GMNNPMP22
SCHEMBL3495050 0.74 LMNA (0.68) LMNAKDM4ETFPI2GMNNPMP22
SCHEMBL13311369 0.74 LMNA (0.57) LMNAKDM4ETFPI2GMNNPMP22
SCHEMBL3494928 0.74 LMNA (0.57) LMNAKDM4ETFPI2GMNNPMP22
SCHEMBL17384921 0.74 LMNA (0.57) LMNAKDM4ETFPI2GMNNPMP22
SCHEMBL9547063 0.74 LMNA (0.62) LMNAKDM4EGMNNPMP22SMN1; SMN2
SCHEMBL9546969 0.74 LMNA (0.62) LMNAKDM4EGMNNPMP22SMN1; SMN2
Endothall SCHEMBL13480837 0.73 TFPI2 (1.00) LMNAKDM4ETFPI2GMNNPMP22
Endothall SCHEMBL55158 0.73 TFPI2 (1.00) LMNAKDM4ETFPI2GMNNPMP22
Endothall SCHEMBL8536404 0.73 TFPI2 (1.00) LMNAKDM4ETFPI2GMNNPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086534-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS Genetic Technologies Limited (AU) 2009-08-12 EP claimed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO claimed
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS PPP1R10, TASP1, PPP5C LMNA 4332/4885KDM4E 1897/4885TFPI2 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.